Dossier overview
3
research areas
3
references
3
handling notes
01
Mechanism of action
Cagrilintide activates calcitonin and amylin implicated in satiety and gastric-emptying regulation. Its lipidation provides extended plasma , enabling weekly dosing alongside other long-acting metabolic peptides.
02
Research applications
- Obesity clinical research (monotherapy and combination)
- Amylin / calcitonin pharmacology
- Combination incretin / amylin therapy research
Evidence at a glance
What's behind this profile
3 citations · 2021–2024
- Human
- 1
- Review
- 2
Studies in human volunteers or patients (incl. early-phase trials).
Narrative or systematic reviews; no primary data.
Publication years
- 21
- 22
- 23
- 24
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 1 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Once-weekly cagrilintide for weight management in people with overweight and obesity
2021
Lau DCW et al. · The Lancet
- Model
- Phase 2 dose-finding double-blind RCT in adults with overweight/obesity
- Sample
- n=706
Cagrilintide doses of 0.3–4.5 mg were associated with dose-dependent mean weight reductions of 6.0%–10.8% versus 3.0% with placebo over 26 weeks.
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
2024
D'Ascanio AM et al. · Cardiology in Review
- Model
- Narrative review
- Sample
- N/A (review)
Reviewed cagrilintide's mechanism, the Phase 2 monotherapy evidence, and the rationale for the CagriSema (cagrilintide + semaglutide) combination.
Amylin analogs for the treatment of obesity without diabetes: present and future
2024
Panou T et al. · Expert Review of Clinical Pharmacology
- Model
- Narrative review
- Sample
- N/A (review)
Reviewed amylin development for non-diabetic obesity and the emerging dual- and triple- combinations including CagriSema.
Evidence caveats
- Cagrilintide is investigational. Most published primary data come from a single Phase 2 dose-finding RCT (Lau 2021). Phase III evidence is accumulating but not yet established at the time of writing.
- The CagriSema combination is a separate clinical-development programme; this profile covers cagrilintide monotherapy evidence.
04
Storage and handling
Trial material follows the clinical trial protocol cold-chain. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Investigational compound — use is restricted to authorised clinical trials and research settings.
- Maintain full batch and supplier traceability.
- Cold-chain handling per clinical trial protocol.